September 6, 2013
Dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are both incretin-related drugs, but sales of the former have grown rapidly since their debut, while those of the latter appear to be stuck. However, with the recent launch of...read more